on Alamar Biosciences, Inc.
Alamar Biosciences Unveils Innovative Blood-Based Assay for Alzheimer's Research
Alamar Biosciences has introduced the NULISAqpcr™ BD-pTau217 Assay. This breakthrough tool is a blood-based method designed to detect brain-derived phosphorylated tau 217 (pTau217), a key biomarker in Alzheimer's research. This is the first single-plex solution that allows precise detection without relying on cerebrospinal fluid collection or PET imaging.
This assay, part of Alamar's proprietary NULISA™ platform, offers exceptional sensitivity and specificity from non-invasive samples. It marks a significant advance in neurodegenerative research by enabling high-throughput analysis with its automated workflow, capable of processing over 220 samples per day.
The assay supports both research and translational studies, being available in single-plex and part of the multiplex NULISAseq™ CNS Disease Panel 120. Alamar aims to drive progress in understanding Alzheimer's pathology and developing disease-modifying therapies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Alamar Biosciences, Inc. news